Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer (FOSCO)
A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma
Sponsor: AIO-Studien-gGmbH
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from AIO-Studien-gGmbH
Listed as NCT00889343, this PHASE2 trial focuses on Colorectal Neoplasms and remains terminated or withdrawn. Sponsored by AIO-Studien-gGmbH, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AIO-Studien-gGmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalen, Germany , Bochum, Germany , Bremen, Germany , Cologne, Germany , Darmstadt, Germany , Datteln, Germany , Dessau, Germany , Dresden, Germany , Eschweiler, Germany , Essen, Germany and 43 more locations